These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 32358890)

  • 1. Cutaneous sıde-effects of the potential COVID-19 drugs.
    Türsen Ü; Türsen B; Lotti T
    Dermatol Ther; 2020 Jul; 33(4):e13476. PubMed ID: 32358890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic.
    Shah M; Sachdeva M; Dodiuk-Gad RP
    Dermatol Ther; 2020 Jul; 33(4):e13524. PubMed ID: 32383251
    [No Abstract]   [Full Text] [Related]  

  • 4. Race to find COVID-19 treatments accelerates.
    Kupferschmidt K; Cohen J
    Science; 2020 Mar; 367(6485):1412-1413. PubMed ID: 32217705
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges.
    Yang X; Liu Y; Liu Y; Yang Q; Wu X; Huang X; Liu H; Cai W; Ma G
    Expert Rev Clin Pharmacol; 2020 Sep; 13(9):957-975. PubMed ID: 32746653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
    Marto N; Monteiro EC
    Acta Med Port; 2020 Jul; 33(7-8):500-504. PubMed ID: 32425152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.
    Li L; Wang X; Wang R; Hu Y; Jiang S; Lu X
    Drug Des Devel Ther; 2020; 14():3001-3013. PubMed ID: 32801640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
    Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
    In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chloroquine and hydroxychloroquine in covid-19.
    Ferner RE; Aronson JK
    BMJ; 2020 Apr; 369():m1432. PubMed ID: 32269046
    [No Abstract]   [Full Text] [Related]  

  • 12. Psychopharmacology of COVID-19.
    Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
    Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.
    Martinez-Lopez A; Cuenca-Barrales C; Montero-Vilchez T; Molina-Leyva A; Arias-Santiago S
    J Am Acad Dermatol; 2020 Dec; 83(6):1738-1748. PubMed ID: 32777318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral treatment of COVID-19.
    Şimşek Yavuz S; Ünal S
    Turk J Med Sci; 2020 Apr; 50(SI-1):611-619. PubMed ID: 32293834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of recommended COVID-19 drugs with commonly used psychotropics.
    Chatterjee SS; Malathesh BC; Das S; Singh OP
    Asian J Psychiatr; 2020 Aug; 52():102173. PubMed ID: 32446195
    [No Abstract]   [Full Text] [Related]  

  • 16. Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?
    Guastalegname M; Vallone A
    Clin Infect Dis; 2020 Jul; 71(15):888-889. PubMed ID: 32211771
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
    Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
    [No Abstract]   [Full Text] [Related]  

  • 18. The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
    Danion F; Ruch Y; Fourtage M; Kaeuffer C; Greigert V; Lefebvre N; Muller J; Nai T; Hansmann Y
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513798
    [No Abstract]   [Full Text] [Related]  

  • 19. [Potential therapeutic drugs for novel coronavirus pneumonia].
    Nie NF; He Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Nov; 43(11):970-974. PubMed ID: 33137863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral therapy for coronavirus disease 2019.
    Gong S; Su J; Yan X; Li F; Hu L; Liu S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 May; 45(5):598-602. PubMed ID: 32879113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.